

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastric, Gastroesophageal Junction and Esophageal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to the results of the Phase II DESTINY-Gastric02 trial, trastuzumab deruxtecan monotherapy demonstrated meaningful responses in patients with HER2-positive advanced gastric or gastroesophageal junction cancer in which of the following settings?
 - a. As first-line therapy
 - b. As second-line therapy
 - c. As third-line therapy
2. Meaningful responses were observed in patients with which of the following targets in the Phase II FAST trial evaluating the addition of zolbetuximab to EOX (epirubicin, oxaliplatin and capecitabine) as first-line therapy for advanced gastric or GEJ adenocarcinoma?
 - a. Claudin 18.2 overexpression
 - b. High tumor mutational burden
 - c. FGFR2b overexpression
 - d. Claudin 18.2 overexpression and high mutational burden
 - e. High mutational burden and FGFR2b overexpression
 - f. All of the above
3. In the Phase III ORIENT-15 trial evaluating the addition of sintilimab to chemotherapy for advanced esophageal squamous cell carcinoma, patients must have received which prior therapy?
 - a. Nivolumab monotherapy
 - b. Nivolumab/ipilimumab
 - c. Pembrolizumab with cisplatin/fluorouracil
 - d. No prior systemic treatment
4. An interim analysis of the Phase III JUPITER-06 trial evaluating chemotherapy/toripalimab versus chemotherapy/placebo for patients with advanced esophageal squamous cell carcinoma demonstrated which overall survival hazard ratio with the addition of toripalimab to chemotherapy?
 - a. 0.26
 - b. 0.47
 - c. 0.58
 - d. 0.79